SlideShare a Scribd company logo
1 of 3
Download to read offline
Lilladher
Prabhudas Zee Entertainment Enterprises
CMP: Rs280 TP: Rs330 Rating: BUY MCap: Rs269.1bn
Paradigm shift in business model from cyclicality to annuity: Broadcasting
industry is likely to witness a paradigm shift in its business model. With the
implementation of digitization, subscription revenues will increase, while the
reliance of broadcasters on advertising will come down. Subscription revenues
for the industry are likely to increase at a CAGR of 26% from Rs69bn in CY13
to Rs220bn in CY18E. We expect Zee’s domestic subscription revenues to
increase at a CAGR of 17.7% over FY14-16E.
Digitization - Soon to become a reality: Though implementation of
digitization has encountered several hurdles leading to a considerable delay,
we believe, digitization is bound to happen sooner than later. With TRAI
upping the ante lately, gross billing has finally kicked off in Phase-I. In Phase-II,
~80-90% of seeding of set top boxes has been completed and Customer
Acquisition Form (CAF) is being collected. We assume gross billing to pick up
in H2FY15E. Delay in implementation of digitization is one of the reasons why
stock has underperformed over the last 12 months. However, strong
subscription trajectory and cash flows should result in a strong performance,
going forward.
Earnings likely to compound at a CAGR of 16%; RoE/RoCEs to inch up by
50bps/120bps by FY16E: With strong advertising growth and implementation
of digitization, we expect Zee’s top-line to increase at a CAGR of 14% over
FY14-16E. EBITDA margins are likely to increase by 180bps to 29.0% by FY16E.
PAT is likely to increase at a CAGR of 16% over FY14-16E, with EPS likely to be
Rs12.5 in FY16E. Consequently, Zee’s RoEs/ROCEs are likely to increase to
21.1%/27.6% by FY16E.
Strong FCFF generation to further strengthen b/s: Going forward, improved
profitability, coupled with limited capex, is likely to translate into strong FCFF
generation for Zee. We expect Zee to generate FCFF of Rs10.5bn/9.5bn in
FY15E/16E, translating into cumulative FCFF of Rs20bn. Debt-free status,
coupled with robust FCFF generation, would further strengthen B/S and
enable it to invest in niche content during the post-digitization era. With
strong earnings growth, debt-free b/s, limited capex, robust FCFF generation,
improvement in return ratios, we believe Zee would continue to trade at
premium valuations.
8/18/2014 47
Key Financials (Rs m)
Y/e March FY12 FY13 FY14 FY15E FY16E
Revenue (Rs m) 30,405 36,996 44,217 49,560 57,505
Growth (%) 1.1 21.7 19.5 12.1 16.0
EBITDA (Rs m) 7,395 9,543 12,043 13,421 16,685
PAT (Rs m) 5,891 7,196 8,921 9,727 12,018
EPS (Rs) 6.1 7.5 9.3 10.1 12.5
Growth (%) (2.7) 22.8 23.1 9.1 23.6
Net DPS (Rs) 1.5 2.0 2.0 2.4 2.7
Source: Company Data, PL Research
Profitability & valuation
Y/e March FY12 FY13 FY14 FY15E FY16E
EBITDA margin (%) 24.3 25.8 27.2 27.1 29.0
RoE (%) 18.0 19.6 20.6 19.3 21.1
RoCE (%) 21.6 24.9 26.4 24.8 27.6
EV / sales (x) 8.7 7.1 6.0 5.2 4.4
EV / EBITDA (x) 35.9 27.5 21.9 19.2 15.2
PER (x) 45.6 37.2 30.2 27.7 22.4
P / BV (x) 7.8 6.8 5.7 5.1 4.4
Net dividend yield (%) 0.5 0.7 0.7 0.9 1.0
Source: Company Data, PL Research
Stock Performance
(%) 1M 6M 12M
Absolute (4.9) 5.1 12.7
Relative to Sensex (9.5) (24.5) (23.6)
Lilladher
Prabhudas Financials
Zee Entertainment Enterprises
8/18/2014 48
Income Statement (Rs m)
Y/e March FY12 FY13 FY14 FY15E FY16E
Net Revenue 30,405 36,996 44,217 49,560 57,505
Direct Expenses 14,311 17,401 20,688 23,303 26,501
% of Net Sales 47.1 47.0 46.8 47.0 46.1
Employee Cost 2,925 3,491 3,905 4,361 5,060
% of Net Sales 9.6 9.4 8.8 8.8 8.8
SG&A Expenses - - - - -
% of Net Sales 0.0 0.0 0.0 0.0 0.0
Other Expenses 5,774 6,561 7,581 8,475 9,258
% of Net Sales 19.0 17.7 17.1 17.1 16.1
EBITDA 7,395 9,543 12,043 13,421 16,685
Margin (%) 24.3 25.8 27.2 27.1 29.0
Depreciation 323 399 501 760 731
PBIT 7,072 9,144 11,541 12,661 15,955
Interest Expenses 50 86 158 50 50
PBT 8,406 10,519 13,190 14,411 17,805
Total tax 2,500 3,337 4,291 4,683 5,786
Effective Tax rate (%) 29.7 31.7 32.5 32.5 32.5
PAT 5,891 7,196 8,921 9,727 12,018
Extraordinary Gain/(Loss) - - - - -
Adjusted PAT 5,891 7,196 8,921 9,727 12,018
Source: Company Data, PL Research
Balance Sheet (Rs m)
Y/e March FY12 FY13 FY14 FY15E FY16E
Share Capital 959 954 21,130 21,130 21,130
Reserves & Surplus 33,396 38,162 26,247 32,068 39,844
Shareholder's Fund 34,355 39,116 47,377 53,198 60,974
Preference Share Capital - - - - -
Total Debt 12 17 17 17 17
Other Liabilities(net) (32) 33 719 658 658
Deferred Tax Liability - - - - -
Total Liabilities 34,335 39,166 48,113 53,873 61,649
Gross Block 11,205 12,306 14,564 15,258 16,005
Less: Depreciation 2,006 2,400 2,901 3,662 4,393
Net Block 9,199 9,906 11,663 11,596 11,613
Capital Work in Progress 201 69 69 69 69
Cash & Cash Equivalent 11,597 13,562 14,295 20,911 26,107
Total Current Assets 25,105 32,051 39,638 46,560 54,968
Total Current Liabilities 8,820 11,393 12,204 13,599 15,248
Net Current Assets 16,285 20,658 27,435 32,961 39,720
Other Assets 337 288 298 298 298
Total Assets 34,335 39,166 48,115 53,875 61,650
Source: Company Data, PL Research
Lilladher
Prabhudas
Disclaimer
8/18/2014 70
BUY : Over 15% Outperformance to Sensex over 12-months Accumulate : Outperformance to Sensex over 12-months
Reduce : Underperformance to Sensex over 12-months Sell : Over 15% underperformance to Sensex over 12-months
Trading Buy : Over 10% absolute upside in 1-month Trading Sell : Over 10% absolute decline in 1-month
Not Rated (NR) : No specific call on the stock Under Review (UR) : Rating likely to change shortly
This document has been prepared by the Research Division of Prabhudas Lilladher Pvt. Ltd. Mumbai, India (PL) and is meant for use by the recipient only as information and is not for circulation. This document is
not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.
The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any
of its affiliates, its directors or its employees accept any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.
Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will
depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.
Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies
referred to in this report and they may have used the research material prior to publication.
We may from time to time solicit or perform investment banking or other services for any company mentioned in this document.
Prabhudas Lilladher Pvt. Ltd.
3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai 400 018, India.
Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209
PL’s Recommendation Nomenclature
Rating Distribution of Research Coverage
32.7%
50.0%
17.3%
0.0%
0%
10%
20%
30%
40%
50%
60%
BUY Accumulate Reduce Sell
%ofTotalCoverage

More Related Content

What's hot

Epic research weakly fundamental report of 10th – 14th november 2014
Epic research weakly fundamental report of 10th – 14th november 2014Epic research weakly fundamental report of 10th – 14th november 2014
Epic research weakly fundamental report of 10th – 14th november 2014Epic Research Limited
 
Orchard presentation gbp a class - feb 15 - dominic
Orchard presentation   gbp a class - feb 15 - dominicOrchard presentation   gbp a class - feb 15 - dominic
Orchard presentation gbp a class - feb 15 - dominicDominic Hardcastle
 
Q3FY15 Recommendation: Maintain hold on Alembic Pharma
 Q3FY15 Recommendation: Maintain hold on Alembic Pharma Q3FY15 Recommendation: Maintain hold on Alembic Pharma
Q3FY15 Recommendation: Maintain hold on Alembic PharmaIndiaNotes.com
 
Project report on zee tv-manendra
Project report on zee tv-manendraProject report on zee tv-manendra
Project report on zee tv-manendraManendra Shukla
 
Decoding the National Pension System (NPS)
Decoding the National Pension System (NPS)Decoding the National Pension System (NPS)
Decoding the National Pension System (NPS)Abhishek Mittal
 
Financial Accounting
Financial AccountingFinancial Accounting
Financial AccountingNavin Bafna
 
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 21 January 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 21 January 2015EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 21 January 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 21 January 2015Epic Research Singapore
 
Q4FY15 result update: IDFC profits trail street expectations
Q4FY15 result update: IDFC profits trail street expectationsQ4FY15 result update: IDFC profits trail street expectations
Q4FY15 result update: IDFC profits trail street expectationsIndiaNotes.com
 
LTFH Strategy Updates & Results - Q4FY17 and FY17
LTFH Strategy Updates & Results - Q4FY17 and FY17LTFH Strategy Updates & Results - Q4FY17 and FY17
LTFH Strategy Updates & Results - Q4FY17 and FY17Anuj Aras
 
Coffee day enterprises
Coffee day enterprisesCoffee day enterprises
Coffee day enterprisessarthak omer
 
Robotics presentation (series_45,_reach_branded)-converted
Robotics presentation (series_45,_reach_branded)-convertedRobotics presentation (series_45,_reach_branded)-converted
Robotics presentation (series_45,_reach_branded)-convertedHo Khanh Ly
 
Intel - stock valuation and analysis model - imran almaleh
Intel - stock valuation and analysis model - imran almalehIntel - stock valuation and analysis model - imran almaleh
Intel - stock valuation and analysis model - imran almalehImran Almaleh
 

What's hot (20)

Epic research weakly fundamental report of 10th – 14th november 2014
Epic research weakly fundamental report of 10th – 14th november 2014Epic research weakly fundamental report of 10th – 14th november 2014
Epic research weakly fundamental report of 10th – 14th november 2014
 
Orchard presentation gbp a class - feb 15 - dominic
Orchard presentation   gbp a class - feb 15 - dominicOrchard presentation   gbp a class - feb 15 - dominic
Orchard presentation gbp a class - feb 15 - dominic
 
1 h13 hcs_ir eng
1 h13 hcs_ir eng1 h13 hcs_ir eng
1 h13 hcs_ir eng
 
Q3FY15 Recommendation: Maintain hold on Alembic Pharma
 Q3FY15 Recommendation: Maintain hold on Alembic Pharma Q3FY15 Recommendation: Maintain hold on Alembic Pharma
Q3FY15 Recommendation: Maintain hold on Alembic Pharma
 
Project report on zee tv-manendra
Project report on zee tv-manendraProject report on zee tv-manendra
Project report on zee tv-manendra
 
Decoding the National Pension System (NPS)
Decoding the National Pension System (NPS)Decoding the National Pension System (NPS)
Decoding the National Pension System (NPS)
 
Financial Accounting
Financial AccountingFinancial Accounting
Financial Accounting
 
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 21 January 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 21 January 2015EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 21 January 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 21 January 2015
 
Q4FY15 result update: IDFC profits trail street expectations
Q4FY15 result update: IDFC profits trail street expectationsQ4FY15 result update: IDFC profits trail street expectations
Q4FY15 result update: IDFC profits trail street expectations
 
Csl daily market update 06102015
Csl daily market update 06102015Csl daily market update 06102015
Csl daily market update 06102015
 
LTFH Strategy Updates & Results - Q4FY17 and FY17
LTFH Strategy Updates & Results - Q4FY17 and FY17LTFH Strategy Updates & Results - Q4FY17 and FY17
LTFH Strategy Updates & Results - Q4FY17 and FY17
 
Daily Stock Market Reports and Stocks to Watch For Tuesday 2018
Daily Stock Market Reports and Stocks to Watch For Tuesday 2018Daily Stock Market Reports and Stocks to Watch For Tuesday 2018
Daily Stock Market Reports and Stocks to Watch For Tuesday 2018
 
Idea
IdeaIdea
Idea
 
Hcs 1 q13_ir_eng
Hcs 1 q13_ir_engHcs 1 q13_ir_eng
Hcs 1 q13_ir_eng
 
Presentation
PresentationPresentation
Presentation
 
Coffee day enterprises
Coffee day enterprisesCoffee day enterprises
Coffee day enterprises
 
Robotics presentation (series_45,_reach_branded)-converted
Robotics presentation (series_45,_reach_branded)-convertedRobotics presentation (series_45,_reach_branded)-converted
Robotics presentation (series_45,_reach_branded)-converted
 
Watching The Street: Singapore
Watching The Street: SingaporeWatching The Street: Singapore
Watching The Street: Singapore
 
Sp q1 commentary2013
Sp q1 commentary2013Sp q1 commentary2013
Sp q1 commentary2013
 
Intel - stock valuation and analysis model - imran almaleh
Intel - stock valuation and analysis model - imran almalehIntel - stock valuation and analysis model - imran almaleh
Intel - stock valuation and analysis model - imran almaleh
 

Similar to Zee Entertainment: Paradigm shift in business model from cyclicality to annuity - Prabhudas Lilladher

Q4FY14 Result: Bajaj Finance continues to reap the benefits of healthy consum...
Q4FY14 Result: Bajaj Finance continues to reap the benefits of healthy consum...Q4FY14 Result: Bajaj Finance continues to reap the benefits of healthy consum...
Q4FY14 Result: Bajaj Finance continues to reap the benefits of healthy consum...IndiaNotes.com
 
Zee Entertainment Enterprises: Good quarter; near-term outlook weak - Prabhud...
Zee Entertainment Enterprises: Good quarter; near-term outlook weak - Prabhud...Zee Entertainment Enterprises: Good quarter; near-term outlook weak - Prabhud...
Zee Entertainment Enterprises: Good quarter; near-term outlook weak - Prabhud...IndiaNotes.com
 
Research report first source solution
Research report first source solutionResearch report first source solution
Research report first source solutionPreeti Srivastava
 
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil FinanceQ2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil FinanceIndiaNotes.com
 
Persistent Systems: Acquired RGen Solutions, Strengthening OPD presence
Persistent Systems: Acquired RGen Solutions, Strengthening OPD presencePersistent Systems: Acquired RGen Solutions, Strengthening OPD presence
Persistent Systems: Acquired RGen Solutions, Strengthening OPD presenceIndiaNotes.com
 
Blue Star Infotech Q1FY15: Revenues grow 13% y-o-y; Positive outlook
 Blue Star Infotech Q1FY15: Revenues grow 13% y-o-y; Positive outlook Blue Star Infotech Q1FY15: Revenues grow 13% y-o-y; Positive outlook
Blue Star Infotech Q1FY15: Revenues grow 13% y-o-y; Positive outlookIndiaNotes.com
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15IndiaNotes.com
 
ACC: Buy for a target of Rs1650
ACC: Buy for a target of Rs1650ACC: Buy for a target of Rs1650
ACC: Buy for a target of Rs1650IndiaNotes.com
 
Q2FY15: Wipro consolidated sales grows 5%
Q2FY15: Wipro consolidated sales grows 5%Q2FY15: Wipro consolidated sales grows 5%
Q2FY15: Wipro consolidated sales grows 5%IndiaNotes.com
 
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas LilladherKSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas LilladherIndiaNotes.com
 
Cipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15ECipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15EIndiaNotes.com
 
CUB-INV-PPT-JUN-2022.pdf
CUB-INV-PPT-JUN-2022.pdfCUB-INV-PPT-JUN-2022.pdf
CUB-INV-PPT-JUN-2022.pdfAbarajIthan2
 
Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015IndiaNotes.com
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndiaNotes.com
 
Petronet LNG: Reports decent set of numbers, hold - Sushil Finance
Petronet LNG: Reports decent set of numbers, hold - Sushil FinancePetronet LNG: Reports decent set of numbers, hold - Sushil Finance
Petronet LNG: Reports decent set of numbers, hold - Sushil FinanceIndiaNotes.com
 
현대카드 Ir 자료 (2016 2 q) jp
현대카드 Ir 자료 (2016 2 q) jp현대카드 Ir 자료 (2016 2 q) jp
현대카드 Ir 자료 (2016 2 q) jpHyundai Finance
 
KPDL_Result Presentation_Q4 and FY15
KPDL_Result Presentation_Q4 and FY15KPDL_Result Presentation_Q4 and FY15
KPDL_Result Presentation_Q4 and FY15Varun Parwal
 
현대카드 Ir 자료 (2016 2 q) en
현대카드 Ir 자료 (2016 2 q) en현대카드 Ir 자료 (2016 2 q) en
현대카드 Ir 자료 (2016 2 q) enHyundai Finance
 

Similar to Zee Entertainment: Paradigm shift in business model from cyclicality to annuity - Prabhudas Lilladher (20)

Q4FY14 Result: Bajaj Finance continues to reap the benefits of healthy consum...
Q4FY14 Result: Bajaj Finance continues to reap the benefits of healthy consum...Q4FY14 Result: Bajaj Finance continues to reap the benefits of healthy consum...
Q4FY14 Result: Bajaj Finance continues to reap the benefits of healthy consum...
 
Zee Entertainment Enterprises: Good quarter; near-term outlook weak - Prabhud...
Zee Entertainment Enterprises: Good quarter; near-term outlook weak - Prabhud...Zee Entertainment Enterprises: Good quarter; near-term outlook weak - Prabhud...
Zee Entertainment Enterprises: Good quarter; near-term outlook weak - Prabhud...
 
634926580024019075
634926580024019075634926580024019075
634926580024019075
 
Research report first source solution
Research report first source solutionResearch report first source solution
Research report first source solution
 
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil FinanceQ2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
 
TCS Fact Sheet Q1 FY15
TCS Fact Sheet Q1 FY15TCS Fact Sheet Q1 FY15
TCS Fact Sheet Q1 FY15
 
Persistent Systems: Acquired RGen Solutions, Strengthening OPD presence
Persistent Systems: Acquired RGen Solutions, Strengthening OPD presencePersistent Systems: Acquired RGen Solutions, Strengthening OPD presence
Persistent Systems: Acquired RGen Solutions, Strengthening OPD presence
 
Blue Star Infotech Q1FY15: Revenues grow 13% y-o-y; Positive outlook
 Blue Star Infotech Q1FY15: Revenues grow 13% y-o-y; Positive outlook Blue Star Infotech Q1FY15: Revenues grow 13% y-o-y; Positive outlook
Blue Star Infotech Q1FY15: Revenues grow 13% y-o-y; Positive outlook
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15
 
ACC: Buy for a target of Rs1650
ACC: Buy for a target of Rs1650ACC: Buy for a target of Rs1650
ACC: Buy for a target of Rs1650
 
Q2FY15: Wipro consolidated sales grows 5%
Q2FY15: Wipro consolidated sales grows 5%Q2FY15: Wipro consolidated sales grows 5%
Q2FY15: Wipro consolidated sales grows 5%
 
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas LilladherKSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
 
Cipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15ECipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15E
 
CUB-INV-PPT-JUN-2022.pdf
CUB-INV-PPT-JUN-2022.pdfCUB-INV-PPT-JUN-2022.pdf
CUB-INV-PPT-JUN-2022.pdf
 
Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
 
Petronet LNG: Reports decent set of numbers, hold - Sushil Finance
Petronet LNG: Reports decent set of numbers, hold - Sushil FinancePetronet LNG: Reports decent set of numbers, hold - Sushil Finance
Petronet LNG: Reports decent set of numbers, hold - Sushil Finance
 
현대카드 Ir 자료 (2016 2 q) jp
현대카드 Ir 자료 (2016 2 q) jp현대카드 Ir 자료 (2016 2 q) jp
현대카드 Ir 자료 (2016 2 q) jp
 
KPDL_Result Presentation_Q4 and FY15
KPDL_Result Presentation_Q4 and FY15KPDL_Result Presentation_Q4 and FY15
KPDL_Result Presentation_Q4 and FY15
 
현대카드 Ir 자료 (2016 2 q) en
현대카드 Ir 자료 (2016 2 q) en현대카드 Ir 자료 (2016 2 q) en
현대카드 Ir 자료 (2016 2 q) en
 

More from IndiaNotes.com

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15IndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesIndiaNotes.com
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoIndiaNotes.com
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityIndiaNotes.com
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16IndiaNotes.com
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtIndiaNotes.com
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...IndiaNotes.com
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...IndiaNotes.com
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CAREIndiaNotes.com
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...IndiaNotes.com
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16EIndiaNotes.com
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...IndiaNotes.com
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyIndiaNotes.com
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyIndiaNotes.com
 
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetTorrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetIndiaNotes.com
 
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...IndiaNotes.com
 

More from IndiaNotes.com (20)

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debt
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARE
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16E
 
Nirmal lupin 06_aug15
Nirmal lupin 06_aug15Nirmal lupin 06_aug15
Nirmal lupin 06_aug15
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, Buy
 
Fce thermax 31_jul15
Fce thermax 31_jul15Fce thermax 31_jul15
Fce thermax 31_jul15
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
 
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetTorrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
 
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
 

Zee Entertainment: Paradigm shift in business model from cyclicality to annuity - Prabhudas Lilladher

  • 1. Lilladher Prabhudas Zee Entertainment Enterprises CMP: Rs280 TP: Rs330 Rating: BUY MCap: Rs269.1bn Paradigm shift in business model from cyclicality to annuity: Broadcasting industry is likely to witness a paradigm shift in its business model. With the implementation of digitization, subscription revenues will increase, while the reliance of broadcasters on advertising will come down. Subscription revenues for the industry are likely to increase at a CAGR of 26% from Rs69bn in CY13 to Rs220bn in CY18E. We expect Zee’s domestic subscription revenues to increase at a CAGR of 17.7% over FY14-16E. Digitization - Soon to become a reality: Though implementation of digitization has encountered several hurdles leading to a considerable delay, we believe, digitization is bound to happen sooner than later. With TRAI upping the ante lately, gross billing has finally kicked off in Phase-I. In Phase-II, ~80-90% of seeding of set top boxes has been completed and Customer Acquisition Form (CAF) is being collected. We assume gross billing to pick up in H2FY15E. Delay in implementation of digitization is one of the reasons why stock has underperformed over the last 12 months. However, strong subscription trajectory and cash flows should result in a strong performance, going forward. Earnings likely to compound at a CAGR of 16%; RoE/RoCEs to inch up by 50bps/120bps by FY16E: With strong advertising growth and implementation of digitization, we expect Zee’s top-line to increase at a CAGR of 14% over FY14-16E. EBITDA margins are likely to increase by 180bps to 29.0% by FY16E. PAT is likely to increase at a CAGR of 16% over FY14-16E, with EPS likely to be Rs12.5 in FY16E. Consequently, Zee’s RoEs/ROCEs are likely to increase to 21.1%/27.6% by FY16E. Strong FCFF generation to further strengthen b/s: Going forward, improved profitability, coupled with limited capex, is likely to translate into strong FCFF generation for Zee. We expect Zee to generate FCFF of Rs10.5bn/9.5bn in FY15E/16E, translating into cumulative FCFF of Rs20bn. Debt-free status, coupled with robust FCFF generation, would further strengthen B/S and enable it to invest in niche content during the post-digitization era. With strong earnings growth, debt-free b/s, limited capex, robust FCFF generation, improvement in return ratios, we believe Zee would continue to trade at premium valuations. 8/18/2014 47 Key Financials (Rs m) Y/e March FY12 FY13 FY14 FY15E FY16E Revenue (Rs m) 30,405 36,996 44,217 49,560 57,505 Growth (%) 1.1 21.7 19.5 12.1 16.0 EBITDA (Rs m) 7,395 9,543 12,043 13,421 16,685 PAT (Rs m) 5,891 7,196 8,921 9,727 12,018 EPS (Rs) 6.1 7.5 9.3 10.1 12.5 Growth (%) (2.7) 22.8 23.1 9.1 23.6 Net DPS (Rs) 1.5 2.0 2.0 2.4 2.7 Source: Company Data, PL Research Profitability & valuation Y/e March FY12 FY13 FY14 FY15E FY16E EBITDA margin (%) 24.3 25.8 27.2 27.1 29.0 RoE (%) 18.0 19.6 20.6 19.3 21.1 RoCE (%) 21.6 24.9 26.4 24.8 27.6 EV / sales (x) 8.7 7.1 6.0 5.2 4.4 EV / EBITDA (x) 35.9 27.5 21.9 19.2 15.2 PER (x) 45.6 37.2 30.2 27.7 22.4 P / BV (x) 7.8 6.8 5.7 5.1 4.4 Net dividend yield (%) 0.5 0.7 0.7 0.9 1.0 Source: Company Data, PL Research Stock Performance (%) 1M 6M 12M Absolute (4.9) 5.1 12.7 Relative to Sensex (9.5) (24.5) (23.6)
  • 2. Lilladher Prabhudas Financials Zee Entertainment Enterprises 8/18/2014 48 Income Statement (Rs m) Y/e March FY12 FY13 FY14 FY15E FY16E Net Revenue 30,405 36,996 44,217 49,560 57,505 Direct Expenses 14,311 17,401 20,688 23,303 26,501 % of Net Sales 47.1 47.0 46.8 47.0 46.1 Employee Cost 2,925 3,491 3,905 4,361 5,060 % of Net Sales 9.6 9.4 8.8 8.8 8.8 SG&A Expenses - - - - - % of Net Sales 0.0 0.0 0.0 0.0 0.0 Other Expenses 5,774 6,561 7,581 8,475 9,258 % of Net Sales 19.0 17.7 17.1 17.1 16.1 EBITDA 7,395 9,543 12,043 13,421 16,685 Margin (%) 24.3 25.8 27.2 27.1 29.0 Depreciation 323 399 501 760 731 PBIT 7,072 9,144 11,541 12,661 15,955 Interest Expenses 50 86 158 50 50 PBT 8,406 10,519 13,190 14,411 17,805 Total tax 2,500 3,337 4,291 4,683 5,786 Effective Tax rate (%) 29.7 31.7 32.5 32.5 32.5 PAT 5,891 7,196 8,921 9,727 12,018 Extraordinary Gain/(Loss) - - - - - Adjusted PAT 5,891 7,196 8,921 9,727 12,018 Source: Company Data, PL Research Balance Sheet (Rs m) Y/e March FY12 FY13 FY14 FY15E FY16E Share Capital 959 954 21,130 21,130 21,130 Reserves & Surplus 33,396 38,162 26,247 32,068 39,844 Shareholder's Fund 34,355 39,116 47,377 53,198 60,974 Preference Share Capital - - - - - Total Debt 12 17 17 17 17 Other Liabilities(net) (32) 33 719 658 658 Deferred Tax Liability - - - - - Total Liabilities 34,335 39,166 48,113 53,873 61,649 Gross Block 11,205 12,306 14,564 15,258 16,005 Less: Depreciation 2,006 2,400 2,901 3,662 4,393 Net Block 9,199 9,906 11,663 11,596 11,613 Capital Work in Progress 201 69 69 69 69 Cash & Cash Equivalent 11,597 13,562 14,295 20,911 26,107 Total Current Assets 25,105 32,051 39,638 46,560 54,968 Total Current Liabilities 8,820 11,393 12,204 13,599 15,248 Net Current Assets 16,285 20,658 27,435 32,961 39,720 Other Assets 337 288 298 298 298 Total Assets 34,335 39,166 48,115 53,875 61,650 Source: Company Data, PL Research
  • 3. Lilladher Prabhudas Disclaimer 8/18/2014 70 BUY : Over 15% Outperformance to Sensex over 12-months Accumulate : Outperformance to Sensex over 12-months Reduce : Underperformance to Sensex over 12-months Sell : Over 15% underperformance to Sensex over 12-months Trading Buy : Over 10% absolute upside in 1-month Trading Sell : Over 10% absolute decline in 1-month Not Rated (NR) : No specific call on the stock Under Review (UR) : Rating likely to change shortly This document has been prepared by the Research Division of Prabhudas Lilladher Pvt. Ltd. Mumbai, India (PL) and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accept any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication. We may from time to time solicit or perform investment banking or other services for any company mentioned in this document. Prabhudas Lilladher Pvt. Ltd. 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai 400 018, India. Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 PL’s Recommendation Nomenclature Rating Distribution of Research Coverage 32.7% 50.0% 17.3% 0.0% 0% 10% 20% 30% 40% 50% 60% BUY Accumulate Reduce Sell %ofTotalCoverage